HOOSIER CANCER RESEARCH NETWORK
PUBLICATIONS

BLADDER

MANUSCRIPTS/JOURNAL ARTICLES


ASCO ABSTRACTS/POSTERS/PRESENTATIONS


Jinxing Li MD, Beth Juliar MA MS, Rafat Ansari MD, Edward Fox MD, Michael Fisch MD, Lawrence Einhorn MD, Christopher Sweeney MD. A Phase II Study of Weekly Paclitaxel (P) and Gemcitabine (G) in Advanced Transitional Cell Carcinoma (TCC) of the Urothelium): A Hoosier Oncology Group Study GU98-2. Accepted as a poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

Christopher J. Sweeney, Bruce J. Roth, Donald S. Kaufman, Steven J. Nicol A Phase II Study of ALIMTA in Patients with Advanced or Metastatic Recurrent Transitional Cell Carcinoma of the Urothelium): A Hoosier Oncology Group Study GU00-13. Accepted as a poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

N.M. Hahn, W.M. Stadler, R.T. Zon, D. Waterhouse, J. Picus, S. Nattam, C.S. Johnson, S.M. Perkins, C.J. Sweeney. A Multicenter Phase II Study of Cisplatin (C), Gemcitabine (G), and Bevacizumab (B) As First-Line Chemotherapy for Metastatic Urothelial Carcinoma (UC); Hoosier Oncology Group GU04-75. Accepted as an oral presentation at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL. J Clin Oncol 27:15s, 2009 (suppl; abstr 5018)

N. M. Hahn, W. M. Stadler, R. Zon, D. M. Waterhouse, J. Picus, S. R. Nattam, C. S. Johnson, S. M. Perkins, M. J. Waddell, C. Sweeney. Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC). Accepted as a poster discussion at the ASCO annual meeting June 4-8, 2010, Chicago IL J Clin Oncol 28:15s, 2010 (suppl; abstr 4541)

S. Lerner, N.M. Hahn, T. Powles, T. A. Gardner, L. Cheng, J.S. Green, D. M. Berney, D. Taber, J. Hudak, J. Landgraf, S. Shen, G. Sonpavde. A Phase II Trial of Neoadjuvant Cisplatin (C), Gemcitabine (G), and Sunitinib (S) in Muscle-Invasive Urothelial Carcinoma (miUC): Results from Hoosier Oncology Group GU07-123 Trial. Accepted as abstract at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr e15173)

N Hahn, S Daneshmand, EM Posadas, MO Koch, R Bihrlie, RFoster, TA Masterson, L Cheng, Z Liu, T Breen, MT Fleming, R Lance, CW Ryan, CL Corless, MD Galsky, AS Alva, C Mitchell, SS Shen, SP Lerner, G Sonpavde. A phase II trial of neoadjuvant dasatinib (Neo-D) in muscle-invasive urothelial carcinoma of the bladder (miUCB): Hoosier Oncology Group GU07-122 trial. Accepted to the General Poster Session (Abstract #4586) at the ASCO Annual Meeting, June 1-5 2012, Chicago IL. J Clin Oncol 30, 2012 (suppl; abstr 4586)
BA Gartrell, NM Hahn, TE Hutson, G Sonpavde, RJ Hauke, A Starodub, AC Small, C-K Tsao, MD Galsky. Phase II trial of gemcitabine and cisplatin plus ipilimumab as first-line treatment for metastatic urothelial carcinoma: Hoosier Oncology Group GU10-148. Accepted as a Poster Presentation at the Trials in Progress Session at the ASCO Annual Meeting, June 1-5, 2012, Chicago, IL. *J Clin Oncol* 30, 2012 (suppl; abstr TPS4676)


**BREAST**

**MANUSCRIPTS/JOURNAL ARTICLES**


Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Monaco F, Seshadri R, Sledge Jr G. Randomized Pilot Trial of Combination Versus Sequential Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer: A Hoosier Oncology Group Trial BRE96-1. *American Society of Clinical Oncology* 17: No. 10 (October), 1999:pp3033-3037

Updated 28JAN2016


ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS


Miller KD, McCaskill-Stevens W, Sisk J, Loesch DM, Sledge Jr G. Randomized Pilot Trial of Taxotere (T) and Doxorubicin (D) as Primary Chemotherapy for Breast Cancer: A Hoosier Oncology Group Trial BRE96-1 and Walther Cancer Institute, Indianapolis, IN. Accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA.


S. R. Malireddy, S. M. Perkins, S. S. Badve, G. W. Sledge, K. Miller. PARP inhibition after preoperative chemotherapy in patients with triple negative breast cancer (TNBC) or known BRCA1/2 mutations: Hoosier Oncology Group BRE09-146. Accepted as a Poster Presentation at the Trials in Progress Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr TPS130)


Miller K, Tong Y, Jones DR, Walsh T, Danso MA, Ma CX, Silverman P, King MC, Badve SS, Perkins SM. Cisplatin with or without rucaparib after preoperative chemotherapy in patients with triple negative breast cancer: Final efficacy results of Hoosier Oncology Group BRE09-146. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 1082)

ESOPHAGEAL

MANUSCRIPTS/JOURNAL ARTICLES


ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS

R Govindan, N. Fineberg, H. McLeod, K. Kesler, N. Hanna, C. Stoner, J. Vinson, R. Mantravadi, L. Einhorn. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Hoosier Oncology Group GI00-16. Accepted to the general poster session at the ASCO annual meeting June 5-8, 2004, New Orleans, LA.
M. M. Sgroi, N. Hanna, A. McCollum, N. Bechar, M. DiMaio, Z. Hammoud, M. Yu, H. Choy, C. Beccera. Pre-Operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group and the University of Texas-Southwestern: **GI05-92**. Accepted to the general poster session at the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL

A.K. Agarwala, N. Hanna, A. McCollum, N. Bechar, M. DiMaio, M. Yu, Y. Tong, C.R. Beccera, H.Choy. Pre-operative Cetuximab and Radiation (XRT) for Patients (pts) with Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas: A Pilot Study from the Hoosier Oncology Group (HOG) and the University of Texas-Southwestern: **GI05-92**. Accepted to the general poster session at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL *J Clin Oncol 27:15s, 2009 (suppl; abstr 4557)*


**GASTROINTESTINAL**

**MANUSCRIPTS/JOURNAL ARTICLES**


Bandealy MT, Gonin R, Loehrer PJ, Einhorn LH. A Prospective Randomized Hoosier Oncology Trial of 5-Fluorouracil versus 5-Fluorouracil Plus Levamisole in the Treatment of Metastatic Colorectal Cancer: A Hoosier Oncology Group (HOG) and Walther Cancer Institute Trial GI89-1. Accepted to the ASCO Annual Meeting May 18-21, 1996, Philadelphia, PA.

Christopher Sweeney MD, David Seitz MD, Rafat Ansari MD, William Pletcher MD, Naveed Chowhan MD, Jake Vinson MHA, Cindy Stoner BS; Patrick Loehrer MD; A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer: A Hoosier Oncology Group Study GI100-2. Accepted to the ASCO annual meeting May 18-21, 2002, Orlando, FL

Chong-Xian Pan MD, Patrick Loehrer MD, Beth Juliar, Rafat Ansari MD, William Pletcher MD, Christopher Sweeney MD. A Phase II Trial of Irinotecan (I), 5-Fluorouracil (F), Leucovorin (L) (IFL), Celecoxib and Glutamine as First Line Therapy for Advanced Colorectal Cancer (CRC): A Hoosier Oncology Group Study GI100-2. Accepted to the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

Prasad Mantravadi MD, Naomi Fineberg PhD, Rafat Ansari MD, Edward Fox MD, Paul Helft MD, Kenneth Kesler MD, Nasser Hanna MD, Lawrence Einhorn MD, Cindy Stoner, Ramaswamy Govindan MD. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC): Preliminary Results from the Hoosier Oncology Group: GI100-16. Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

R Govindan, N. Fineberg, H. McLeod, K. Kesler, N. Hanna, C. Stoner, J. Vinson, R. Mantravadi, L. Einhorn. A Phase II Study of Cisplatin, 5-Fluorouracil (5-FU), Radiation (RT) and Celecoxib in Patients with Resectable Esophageal Cancer (EC) Hoosier Oncology Group: GI00-16. Accepted to the ASCO annual meeting June 5-8, 2004, New Orleans, LA.


S. Shadha, M. Yu, J. Picus, J. Bufill, W. Harb, M. Burns, J. Spittler, J. Flynn, Y. Zeng, G. Vance, C. Currie, J. Wu, P. J. Loehrer, E.G. Chiorean. Phase I study of everolimus (RAD001) with Irinotecan (Iri) and Cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Oncology Group GI05-102, final report. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 3587)

Chiorean EG, Picus J, Breen T, Ansari RH, Harb WA, Burns M, Spittler AJ, Loehrer PJ. Phase I/II study of everolimus (E) with irinotecan (Iri) and cetuximab (C) in 2nd line metastatic colorectal cancer (mCRC): Hoosier Cancer Research Network GI05-102. Accepted as Poster Presentation at General Poster Session at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr 3618)
GYNECOLOGIC

MANUSCRIPTS/JOURNAL ARTICLES

Achilles J. Fakiris, Higinia R. Cardenes, David H. Moore, Shailaja R. Reddy, Katherine Y. Look, Constantin T. Yiannoutsos, Marcus E. Randall. Indiana University School of Medicine, Indianapolis, IN. Intraperitoneal radioactive phosphorus ($^{32}$P) and vaginal brachytherapy as adjuvant treatment for uterine papillary serous carcinoma and clear cell carcinoma: A Phase II Hoosier Oncology Group Study GYN97-1. *Gynecologic Oncology, 2005; 96: 818-823*


ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS


Daniela Matei, Robert E. Emerson, Nancy Menning, Jeanne Schilder, John McClean, Greg Sutton, Doyle Stephens, Misty Witherite, Charles Whalen, David H. Moore. Clinical Activity of Imatinib Mesylate (Gleevec) in Combination with Docetaxel In Patients With Advanced, Platinum-Resistant Ovarian Cancer Or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN03-62. Accepted to the ASCO Annual Meeting June 2-6, 2006, Atlanta, GA


HEAD AND NECK

MANUSCRIPTS/ARTICLES


ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS

Arquette MA, Mortimer JE, Loehr PJ, Mandanas RA. A Phase II Hoosier Oncology Group Trial of interferon Alpha-2b (IFN) added to Cisplatin (CDDP) and 5-Fluorouracil (FU) in Recurrent or Metastatic Head and Neck Cancer: A Hoosier Oncology Group and Walther Cancer Institute Trial: **HN90-1.** Accepted to the ASCO Annual Meeting, May 14th - 17th, 1994, Dallas, TX

**HEMATOLOGY**

**MANUSCRIPTS/JOURNAL ARTICLES**


**ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS**

Daniel Vaena, Larry Cripe, Lawrence Einhorn, Paul Walker, Kenneth Pennington, Carol Young, Cindy Stoner. Phase II Study of Low-Dose Topotecan in Myelodysplastic Syndromes: A Hoosier Oncology Group Study **MDS98-1.** Accepted as a poster presentation for ASCO Annual Meeting May 18-21, 2002, Orlando, FL.

Rafat Abonour, Kristen Ganjoo, Christopher Fausel, Constantin Yiannoutsos, Beth E. Juliar, Lisa Wood, Gina Smith, Paul Walker, Larry Cripe. A Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma, A Hoosier Oncology Group Trial: **MM01-21.** Accepted as a poster presentation for ASH Annual Meeting December 6-9, 2003, San Diego, CA.
Final Report of a Phase II Study of Oral Cyclophosphamide, Thalidomide, and Prednisone (CTP) for Patients with Relapsed or Refractory Multiple Myeloma: A Hoosier Oncology Group Trial: **MM01-21. Accepted as a poster presentation for the ASCO Annual Meeting, May 13 - 17, 2005, Orlando, FL**

**LYMPHOMA**

**MANUSCRIPTS/JOURNAL ARTICLES**


**MELANOMA**

**MANUSCRIPTS/JOURNAL ARTICLES**


Chapman PB, Einhorn LH, Meyers ML, Saxman SB, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM. A Phase III Multicenter Randomized Trial of the Dartmouth Regimen Versus Dacarbazine Alone in Patients with Metastatic Melanoma: A MSK Cancer Center, New York, NY; Indiana University Medical Center, Indianapolis, IN; University of Pennsylvania Medical Center, Philadelphia, and University of Pittsburgh Medical Center, Pittsburgh, PA; Dartmouth Hitchcock Medical Center, Lebanon, NH; Hoosier Oncology Group, Indianapolis, IN; and ECOG, Boston, MA. **J Clinical Oncology, Vol. 17, number 9, September 1999; pp2745-2751**

**ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS**


Updated 28JAN2016
Saxman SB, Meyers ML, Chapman PB, Destro AN, Panageas KS, Begg CB, Monaco F, Agarwala SS, Schuchter LM, Ernstoff MS, Einhorn LH, Kirkwood JM, Houghton AN. A Phase III Multicenter Randomized Trial of DTIC, Cisplatin, BCNU and Tamoxifen Versus DTIC Alone in Patients with Metastatic Melanoma: A Hoosier Oncology Group and Walther Cancer Institute trial **MEL91-1**, Indianapolis, IN. *Accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA*

**PANCREATIC**

**MANUSCRIPTS/ARTICLES**


Mortimer J, Weber G, Fracasso P, Pletcher W, Ansari R. Phase I-II Study of Zidovudine (AZT) and Methotrexate (MTX) in Advanced Pancreatic Cancer and Hepatoma: A Hoosier Oncology Group and Walther Cancer Institute Trial **G191-1**. *Accepted to the ASCO Annual Meeting, May 14th - 17th, 1994, Dallas, Texas.*

Picus J, Dickerson G, Logie K, Ansari R, Markham R, Spiridonidis C. A Phase II Study of Unresectable Pancreatic Cancer Treated with 5-FU and Leucovorin with Radiation Therapy: A Hoosier Oncology Group and Walther Cancer Institute Trial **G189-2**. *Accepted to the ASCO Annual Meeting, May 14th - 17th, 1994, Dallas, Texas*

**ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS**

Bryan P Schneider, Kristen N Ganjoo, Lawrence H Einhorn, Joel Picus, Farid Fata, Patrick J Loehrer, Cindy Stoner. Phase II study of gemcitabine and docetaxel in combination for advanced pancreatic cancer: Hoosier Oncology Group **G198-1**. *Accepted as a poster presentation with discussion for ASCO annual meeting May 18-21, 2002, Orlando, FL.*
MANUSCRIPTS/ARTICLES


ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS


J. Sharma, C. T. Yiannoutsos, N. M. Hahn, C. Sweeney. Prognostic value of suppressed markers of bone turnover (BTO) after 6 months of androgen deprivation therapy (ADT) in prostate cancer: Hoosier Oncology Group GU02-41. Accepted to the general poster session at the ASCO Annual Meeting June 4-8 2011, Chicago, IL. J Clin Oncol 29: 2011 (suppl; abstr 4594)

QUALITY OF LIFE/CANCER CONTROL

MANUSCRIPTS/ARTICLES


**ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS**

R. M. Navari, L. H. Einhorn, P. J. Loehrser, S. D. Passik, J. Vinson, J. McClean, N. Chowhan, N. Hanna, C. Calley, M. Yu. A Phase II Trial of Olanzapine (Zyprexa) and Palonosetron (Aloxi) for the Prevention of Chemotherapy Induced Nausea and Vomiting: Hoosier Oncology Group QL03-70. Accepted to the ASCO annual meeting June 2-6, 2006, Atlanta, Georgia


Steve Passik, Patrick Loehrer, Rudolph Navari, Cindy Nagy, Jeanette Sawi, SinHo Jung; A Phase I Trial of Olanzapine (ZYPREXA) For the Prevention of Delayed Emesis in Cancer Patients Receiving Chemotherapy: A Hoosier Oncology Group Study QL00-4. Accepted as a poster presentation for ASCO annual meeting May 18-21, 2002, Orlando, FL.


M.J. Brames, E. Johnston, C.R. Nichols, J. Picus, D.J. Vaughn, C.A. Fausel, T.E. Breen, M. Yu, and L.H. Einhorn. Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study QL05-37. Accepted as a Poster Presentation at the International Symposium of the Multinational Association of Supportive Care in Cancer, June 24-26, 2010 Vancouver, Canada.

M.J. Brames, J. Picus, M. Yu, E. Johnston, B. Bottema, C. Williams, and L.H. Einhorn. Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study QL05-37. Accepted as an Oral Presentation at the Oral Abstract Session (Abstract # 9013) at the ASCO Annual Meeting, June 4-8 2011, Chicago, IL.

M.J. Brames, J. Picus, M. Yu, E. Johnston, B. Bottema, C. Williams, and L.H. Einhorn. Phase III double blind placebo controlled crossover study evaluating a 5HT3 antagonist + dexamethasone +/- aprepitant in germ cell tumor patients receiving 5 day cisplatin combination chemotherapy. A Hoosier Oncology Group study QL05-37. Accepted as an Oral Presentation (Abstract # A-327-0011-00199) to the 2011 International Symposium of the Multinational Association of Supportive Care in Cancer, June 23-25, Athens, Greece.
Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Oncology Group QL12-153. Accepted as a TiP poster at the genitourinary (non-prostate) cancer general poster session at the ASCO Annual Meeting, May 30 – June 3, 2014, Chicago IL. J Clin Oncol 32:5s, 2014 (suppl; abstr TPS4594)

Phase II study of fosaprepitant plus 5HT3 receptor antagonists plus dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: Hoosier Cancer Research Network QL12-153. Accepted for poster presentation at the MASCC/ISOO Annual Meeting on Supportive Care in Cancer, June 25-27, 2015, Copenhagen Denmark.

Brames MJ, Case-Eads S, Hanna NH, Fausel CA, Breen T, Einhorn LH. Phase II study of fosaprepitant +5HT3 receptor antagonist + dexamethasone in patients with germ cell tumors undergoing 5-day cisplatin-based chemotherapy: A Hoosier Cancer Research Network Study QL12-153. Accepted as an electronic publication at the ASCO Annual Meeting, May 29-June 2, 2015, Chicago IL. J Clin Oncol 33:5s, 2015 (suppl; abstr e20737)

**RENAL**

**MANUSCRIPTS/ARTICLES**


**ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS**


TE Hutson, LH Dang, RC Lauer, A Starodub, RJ Hauke, MD Galsky, KA Bylow, T Logan, CL Cowey, DC Bibby, G Kremmidiotis, EE Doolin, TC Lavranos, G Sonpavde, NM Hahn, C Sweeney, J Sarantopoulos. Phase I results of a phase I/II trial of BNC105P with everolimus in metastatic renal cell carcinoma (mRCC) patients previously treated with VEGFR tyrosine kinase inhibitors: Hoosier Oncology Group GU09-145. Accepted to the General Poster Session at the ASCO Annual Meeting, June 1-5, 2012, Chicago IL. *J Clin Oncol* 30, 2012 (suppl; abstr 4603)


**THORACIC**

**MANUSCRIPTS/ARTICLES**


Nasser Hanna, Paul Bunn, Jr., Corey Langer, Lawrence Einhorn, Troy Guthrie, Jr., Thaddeus Beck, Rafat Ansari, Peter Ellis, Michael Byrne, Mark Morrison, Subramanian Hariharan, Benjamin Wang, Alan Sandler. Randomized Phase II Trial Comparing Irinotecan/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer LUN00-12. *J Clin Oncol* 2006; 24:2038-2046


Hanna, Nasser; Neubauer, Marcus; McGarry, Ronald; Govindan, Ramaswamy; Johnson, Cynthia; Yiannoutsos, Constantine; Breen, Tim; White, Angela; Ansari, Rafat;Einhorn, Lawrence. Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): LUN01-24/USO-023: B5-01: *Journal of Thoracic Oncology*. 2(8):S346, August 2007


Jalal, Shadia MD; Ansari, Rafat MD; Govindan, Ramaswamy MD; Bhatia, Sumeet MD; Bruetman, Daniel MD; Fisher, William MD; Masters, Gregory MD; White, Angela MBA; Stover, Daniel MT ; Yu, Menggang PhD; Hanna, Nasser MD. Pemetrexed in Second Line and beyond Small Cell Lung Cancer: A Hoosier Oncology Group Phase II Study **LUN04-78**. *Journal of Thoracic Oncology*. 4(1):93-96, January 2009.


Jalal, Shadia; Bedano, Pablo; Einhorn, Lawrence; Bhatia, Sumeet; Ansari, Rafat; Bechar, Naftali; Koneru, Karuna; Govindan, Ramaswamy; Wu, Jingwei; Yu, Menggang; Schneider, Bryan; Hanna, Nasser. Paclitaxel Plus Bevacizumab in Patients with Chemosensitive Relapsed Small Cell Lung Cancer: A Safety, Feasibility, and Efficacy Study from the Hoosier Oncology Group **LUN05-99**. *Journal of Thoracic Oncology*. 5(12):2008-2011, December 2010. doi: 10.1097/JTO.0b013e3181f7b6e


**ASCO ABSTRACTS/POSTERS/PRESENTATIONS/OTHER PRESENTATIONS**


Bhatia S, Sandler A, Ansari R, Monaco F, Einhorn LH. Phase II Study of Paclitaxel Carboplatin and Radiation Therapy for Locally Advanced or Inoperable Non-Small Cell Lung Cancer (NSSLC): A Hoosier Oncology Group and Walther Cancer Institute Trial LUN97-1. Accepted to the ASCO annual meeting May 15-18, 1999, Atlanta, GA

Bhatia S, Ng E, Ansari A, Bufill J, Litrell D, Monaco F, Hanna M, Einhorn LH, Sandler A. A Phase II Study of Paclitaxel and Gemcitabine in Patients with Advanced Non Small Cell Lung Cancer -A Hoosier Oncology Group (HOG) Trial LUN98-1. Accepted to the ASCO annual meeting May 20-23, 2000, New Orleans, Louisiana.


Nasser Hanna, Frances A Shepherd, Rafael Rosell, Jose R Pereira, Filippo De Marinis, Frank V Fossella, Louis Kayitalire, Sofia Paul, Lawrence Einhorn, Paul A Bunn. A Phase III Study of Pemetrexed vs Docetaxel in Patients with Recurrent Non-Small Cell Lung Cancer (NSCLC) who were Previously Treated with Chemotherapy: A Hoosier Oncology Group Study LUN01-15. Presented at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL

A Sandler, C Langer, P Bunn, L Einhorn. A Randomized Phase III Trial Comparing CPT-11 (Irinotecan HCl; Camptosar Injection)/Cisplatin with Etoposide/Cisplatin in Patients with Previously Untreated, Extensive, Small-Cell Lung Cancer: A Hoosier Oncology Group Study **LUN00-12.** *Poster presentation at the ASCO annual meeting May 31-June 3, 2003, Chicago, IL*


A Sandler, C Langer, P Bunn, L Einhorn. Interim Safety Analysis of Irinotecan and Cisplatin Combination Chemotherapy for Previously Untreated Extensive Small Cell Lung Cancer **LUN00-12.** *Accepted to the ASCO annual meeting May 13-17, 2005 in Orlando, Florida*

P. Bedano, M. Neubauer, R. Ansari, R. Govindan, L. Einhorn, D. Bruetman, A. White, T. Breen, B. Juliari, N. Hanna. Phase III Study of Cisplatin (P) plus Etoposide (E) with Concurrent Chest Radiation (XRT) followed by Docetaxel (D) vs. Observation in Patients (pts) with Stage III Non-small Cell Lung Cancer (NSCLC): An Interim Toxicity Analysis of Consolidation Therapy **LUN01-24.** *Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia*


A. Agarwala, L. Einhorn, W. Fisher, D. Bruetman, J. McClean, D. Taber, M. Titzer, B. Juliari, T. Breen, N. Hanna. Gefitinib plus Celecoxib in Chemotherapy-Naive Patients with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC): A Phase II Study from the Hoosier Oncology Group **LUN02-50.** *Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia*

N. Hanna, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fishe, N. Chowhan, S. Nattam, C. Yiannoutsos, L. Einhorn: Phase III trial of cisplatin (P) plus etoposide (E) plus concurrent chest radiation (XRT) with or without consolidation docetaxel (D) in patients (pts) with inoperable stage III non-small cell lung cancer (NSCLC): LUN01-24. Poster presentation at Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

F.O. Ademuyiwa, N. Hanna, C. Johnson, T. Breen, C. Yiannoutsos, A. White: Multivariate Analysis of Prognostic Variables Associated with Survival from a Phase III Study of Cisplatin (P) plus Etoposide (E) plus Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients with Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC) LUN01-24. Poster accepted to the 7th Annual Targeted Therapies of the Treatment of Lung Cancer, Santa Monica, CA – February 22-24, 2007.

M. M. Sgroi, M. Neubauer, R. Ansari, R. Govindan, D. Bruetman, W. Fisher, C. Johnson, T. Breen, C. Yiannoutsos, N. Hanna: An analysis of elderly patients (pts) treated on a phase III trial of cisplatin (P) plus etoposide (E) with concurrent radiotherapy (CRT) followed by docetaxel (D) vs observation (O) in pts with stage III non small cell lung cancer (NSCLC) LUN01-24. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

F. Ademuyiwa, C. Johnson, A. White, T. Breen, J. Harvey, M. Neubauer, N. Hanna: Prognostic Factors For Survival In Patients With Unresectable Stage III Non-Small Cell Lung Cancer From a Phase III Randomized Trial From The Hoosier Oncology Group LUN01-24. Poster accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.


V. Cook, N. Hanna, T. Breen, A. White, J. Wu: Predictors of toxicity to consolidation docetaxel (D) following cisplatin (P) plus etoposide (E) plus concurrent radiation (XRT) in patients (pts) with stage III non-small cell lung cancer (NSCLC) treated on a phase III randomized trial LUN01-24. Abstract accepted to Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

S. Jalal, S. Bhatia, L. Einhorn, R. Ansari, N. Bechar, R. Govindan, K. Koneru, P. Bedano, J. Wu, N. Hanna. Paclitaxel (P) plus bevacizumab (B) in patients (pts) with Chemosensitive Relapsed Small Cell Lung Cancer (SCLC): A Safety, Feasibility and Efficacy trial from the Hoosier Oncology Group **LUN05-99**. *Accepted to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL*

L. Mina, M. Neubauer, R. Ansari, R. Govindan, L. Einhorn, W. Fisher, D. Bruetman, N. Chowhan, C. Johnson, N. Hanna. Phase III Trial of Cisplatin (P) plus Etoposide (E) plus Concurrent Chest Radiation (XRT) with or without Consolidation Docetaxel (D) in Patients (pts) with Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): **LUN01-24/USO-023**; Updated Results. *Accepted as a poster presentation to the ASCO Annual Meeting, May 30-June 3, 2008, Chicago, IL*


E. M. Casey, W. Harb, D. Bradford, J. Bufill, S. Nattam, J. Patel, W. Fisher, J. E. Latz, J. Wu, N. Hanna. Randomized, Double-Blind, Multicenter, Phase II Study of Pemetrexed (PEM), Carboplatin (CARBO), Bevacizumab (BEV) with Enzastaurin (ENZ) or Placebo (PBO) in Chemo-Naïve Patients with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group **LUN06-116**. *Accepted to the general poster session (abstract #8035) at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL*

T. Al Baghdadi, S. Bhatia, W. Harb, J. Maher, J. McClean, S. Nattam, D. Taber, M. Yu, C. Johnson and N. Hanna. Erlotinib and bevacizumab in chemotherapy naïve performance status 2 patients with advanced non-small-cell lung cancer **LUN04-77**. *Accepted (abstract #e19082) at the ASCO annual meeting May 29-June 2, 2009, Orlando, FL*


TRIAL MANAGEMENT

MANUSCRIPTS/ARTICLES


PRESENTATIONS

